KPIs & Operating Metrics(New)
Aesthetics Revenue By CategoryAesthetics Revenue By Category AnnualAesthetics Revenue By GeographyAesthetics Revenue By Geography AnnualBreakdown Of AssetsEmployee StatisticsEye Care Revenue By CategoryEye Care Revenue By Category AnnualEye Care Revenue By GeographyEye Care Revenue By Geography AnnualGross MarginGross Margin %Gross Margin AnnualGross Margin Annual %Hematology Oncology Revenue By CategoryHematology Oncology Revenue By Category AnnualHematology Oncology Revenue By GeographyHematology Oncology Revenue By Geography AnnualImmunology Revenue By CategoryImmunology Revenue By Category AnnualImmunology Revenue By GeographyImmunology Revenue By Geography AnnualIncome Before Income Taxes By RegionLong Lived Assets By RegionNeuroscience Revenue By CategoryNeuroscience Revenue By Category AnnualNeuroscience Revenue By GeographyNeuroscience Revenue By Geography AnnualNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Opex As A % Of RevenueOPEX SegregationOther Key Products Revenue By CategoryOther Key Products Revenue By Category AnnualOther Key Products Revenue By GeographyOther Key Products Revenue By Geography AnnualProperty & Equipment BreakdownRevenueRevenue By GeographyRevenue By Geography %Revenue By Geography AnnualRevenue By Geography Annual %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %Revenue By Ship To LocationRevenue By Ship To Location %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AbbVie (ABBV) Revenue (2016 - 2024)

AbbVie (ABBV) has disclosed Revenue for 14 consecutive years, with $16.6 billion as the latest value for Q4 2025.

  • Quarterly Revenue rose 10.04% to $16.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $61.2 billion through Dec 2025, up 8.57% year-over-year, with the annual reading at $61.2 billion for FY2025, 8.57% up from the prior year.
  • Revenue for Q4 2025 was $16.6 billion at AbbVie, up from $15.8 billion in the prior quarter.
  • The five-year high for Revenue was $16.6 billion in Q4 2025, with the low at $12.2 billion in Q1 2023.
  • Average Revenue over 5 years is $14.3 billion, with a median of $14.4 billion recorded in 2021.
  • The sharpest move saw Revenue surged 50.95% in 2021, then dropped 9.7% in 2023.
  • Over 5 years, Revenue stood at $14.9 billion in 2021, then rose by 1.58% to $15.1 billion in 2022, then decreased by 5.42% to $14.3 billion in 2023, then increased by 5.6% to $15.1 billion in 2024, then increased by 10.04% to $16.6 billion in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $16.6 billion, $15.8 billion, and $15.4 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.